(Q35222575)

7 August 2017

title

Government use licenses in Thailand: an assessment of the health and economic impacts (English)

1 reference

7 August 2017

0 references

5

Yot Teerawattananon

1 reference

7 August 2017

3

Sripen Tantivess

1 reference

7 August 2017

Inthira Yamabhai

1

1 reference

7 August 2017

Adun Mohara

series ordinal

2

1 reference

7 August 2017

Kakanang Chaisiri

series ordinal

4

1 reference

7 August 2017

publication date

14 August 2011

1 reference

7 August 2017

published in

Globalization and Health

1 reference

7 August 2017

volume

7

1 reference

7 August 2017

page(s)

28

1 reference

Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis

7 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176479

A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK

27 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1744-8603-7-28

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1744-8603-7-28

Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1744-8603-7-28

The cost-effectiveness analysis of initiating HIV/AIDS treatment with efavirenz-based regimens compared with nevirapine-based regimens in Thailand.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176479

Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176479

TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176479

Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3176479

Universal coverage and its impact on reproductive health services in Thailand

26 September 2018

1 reference

12 December 2020

Ensuring access to essential medicines in the developing countries: a framework for action

1 reference

12 December 2020

Thailand and the compulsory licensing of efavirenz

1 reference

12 December 2020

Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.

1 reference

12 December 2020

Identifiers

DOI

10.1186/1744-8603-7-28

1 reference

Dimensions Publication ID

7 August 2017

0 references

1 reference

7 August 2017

1 reference